77 results about "Proteomics methods" patented technology

The present invention concerns the identification and detection of maternal serum biomarkers of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency using global proteomic approaches. The invention further concerns the identification of maternal serum biomarkers for detection of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency during early gestation.

The invention provides a polypeptide marker for early diagnosis of diabetes mellitus. The operating method comprises the following steps: establishing an in-vitro simulated glycosylation model by selecting human peripheral blood high-abundant protein HAS, performing enzyme digestion under optimized conditions, performing 18O marking on a blank control group sample subjected to enzyme digestion, mixing the blank control group sample with a reaction group sample subjected to parallel treatment by using 16O according to a volume percent of 1:1, and performing HPLC/ESI-TOFMS detection. According to quantitative analysis of HSA peptide fragments, a peptide fragment, which is the most difficultly modified by glucose and is shown as SEQ ID NO.1, serves as an internal standard peptide fragment, a ratio of a peptide fragment which is easily subjected to glycosylation modification to the peak area of the internal standard peptide fragment is used for measuring the glycosylation modification degree of a glucose sensitive peptide, and according to a proteomics method, three peptide fragments, namely FKDLGEENFK, LDELRDEGK and KVPQVSTPTLVEVSR are finally discovered to serve as biological markers to be used for early diagnosis of diabetes mellitus.

By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A−/−) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

The invention discloses a method for acquiring a two-dimensional strawberry electrophoresis differential protein map. The method comprises the following steps: (1) extracting proteins; (2) performing first-dimensional IPG isoelectric focusing electrophoresis; (3) balancing an adhesive tape; (4) transferring the adhesive tape and performing SDS-polyacrylamide gel electrophoresis; and (5) performing gel scanning and image analysis. An inventor considers the characteristic that strawberry leaves are rich in polysaccharide polyphenol substances in the invention process, the strawberry leaf protein is subjected to repeated precipitation extraction by virtue of acetone, the lysate formula is improved, the centrifugal rate, the cleaning frequency of crude protein precipitations and concentration of urea in lysate are improved, and a set of differential two-dimensional electrophoresis proteomics method suitable for strawberry leaves is constructed, so that the high-quality strawberry protein differential map is obtained. The method can be used for obtaining the two-dimensional strawberry leaf protein electrophoresis gel map with clear protein points, a large number of proteins, uniform protein distribution and a clear background.

The invention discloses a method for measuring ancient cowhair micro-trace based on proteomics. A soil sample of the ancient cowhair micro-trace, a soil sample of a surface soil layer and a soil sample of a raw soil layer are extracted and separated, protein is effectively separated by a two-dimensional electrophoretic technique, the electrophoretic results of the three samples are compared, the influence that the soil contains protein and the interference of external factors are excluded, stripes in the electrophoretic results are cut off and subjected to in-gel digestion, mass spectrometric analysis is conducted, and protein identification can be realized by comparing the mass spectrometric analysis result with the amino acid sequence in a protein database. The ancient cowhair micro-trace is measured by a proteomic method, the problem that the common analysis test is helpless during analysis of micro-trace residues is solved, the protein varieties of the samples are obtained accurately through proteomic measurement, and whether the micro-trace sample is the cowhair micro-trace is judged, so that on one hand, the method is high in sensitivity and is simple and convenient to operate, and on the other hand, the use amount of the samples is small.

Biomarkers have been discovered that are capable of identifying intra-amniotic inflammation. A single biomarker or combination of biomarkers can be used to qualify the risk of preterm delivery in a patient, provided that at least one of the biomarkers is a calgranulin, preferably calgranulin A or C. The result is a rapid and reliable proteotmic approach to identifying intra-amniotic inflammation. In particular, the concentrations of the biomarkers correlate with the magnitude of intra-amniotic inflammation and, hence, of preterm delivery.

Through determination of the presence or absence of proteomic biomarkers within an amniotic environment, the present invention provides for the identification of the condition(s) within the amniotic environment and allows for predictive indication of the success of a pregnancy under the condition(s) and courses of treatment for the condition(s). The present invention further allows for a predictive indication of the success of a cerclage procedure performed on a cervix which supports the amniotic environment under the condition(s).

The present invention provides for a proteomic approach to grading gliomas, and for predicting patient survival. In addition to employing global protein expression patterns, such as by mass spectrometry, particular target proteins whose expression is altered in various gliomas can be used to predict the stage/classificiation of a glioma, as well as to indicate whether a given patient will be a short- or long-term survivor.

Provided are a method for generating a data set for integrated proteomics analysis, whereby expression level variations of both of proteins and genes can be integrally united together and, moreover, highly accurate and appropriate analysis results can be obtained compared with the existing cases where the expression variation amount of proteins or genes is singly analyzed, an integrated proteomics analysis method, a method for identifying a protein causative of a disease or the like using these methods, and a method of using the same???. The aforesaid method for generating a data set for integrated proteomics analyses comprises: a protein identity number-assigning step for assigning common identity numbers to the expression variation amount data of individual proteins; a gene identity number-assigning step for assigning common identity numbers to the expression variation amount data of individual genes; a data-binding step for binding together the set of the expression variation amount data; a data-rejecting step for rejecting, among the individual expression variation amount data constituting the thus bound data set, data showing a p-value equal to or greater than a specific level; and a data-selecting step for selecting one data, from a set of data having the same common identity number assigned thereto, on the basis of a definite requirement to thereby generate the data set to be subjected to integrated proteomics analyses. Further, the data set for integrated proteomics analyses thus generated is subjected to GO analysis and network analysis to thereby identify a protein causative of a disease, a pathological condition or the like. Furthermore, the causative protein thus identified is usable, for example, a tumor marker or a clinical target.

Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and/or 14-3-3-theta and/or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated.

The invention discloses an aptamer-polypeptide compound probe as well as a preparation method and application thereof. The aptamer-polypeptide compound probe has a following structure, and the structural formula is as shown in the specification, wherein R1 is an aptamer HB5, and the R2 is a substrate polypeptide. According to the aptamer-polypeptide compound probe disclosed by the invention, the aptamer technology is combined with a targeted proteomics technology, high specificity and high affinity of an aptamer recognized target are combined with high sensitivity, high selectivity and wide dynamic range detected by the targeted proteomics technology, and a brand new quasi-targeted proteomics method for quantitative HER2 proteins is developed.

Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.

The invention discloses a method for identifying silk types of antique silk fabrics. Three confused antique silk fabrics are grouped; a Na2CO3 solution with a mass fraction of 0.5% is adopted to carry out degumming; after steps of decolorization and waxy oil removal, silk fibroin is dissolved by using a cupriethy lenediamine solution, and purification is carried out by using a dialysis method and an ultrafiltration method together so as to complete extraction of the silk fibroin; enzymolysis is carried out by using an in-solution digestion method; then obtained products are subjected to mass spectrometry by HPLC-MS/MS; results are compared with a database to identify the silk types of the three antique silk fabrics. According to the method disclosed by the invention, detection limitation of a general detection analysis method is overcome, so that even antique silk fabrics in a poor storage state can also be distinguished and identified; the silk types of the antique silk fabrics are identified by adopting a proteomics method, and in the detecting process, an in-solution digestion technology is used, so that the experiment operation is simple and convenient; due to adoption of the proteomics method for identifying the silk types of the antique silk fabrics, the method is high in sensitivity, high in accuracy and small in use quantity of samples.

The invention relates to a method and system for identifying a protein, especially to a proteomic method and system for efficiently identifying polyclonal antibodies. The method includes the followingsteps: (1) a step of sample treatment, namely a step of performing enzymatic hydrolysis treatment on a to-be-tested protein sample by using multiple enzymes in series; (2) a step of liquid chromatography-mass spectrometry detection, namely a step of performing liquid chromatography separation and mass spectrometric detection on peptide fragments after the enzymatic hydrolysis treatment; and (3) astep of data analysis, namely a step of filtering mass spectrometry original down data, performing database searching identification of the mass spectrometry data according to a constructed databaseto obtain identified peptide fragment information, and performing merging according to the identified peptide fragment information to obtain the reliable to-be-tested protein. The method and system for identifying a protein provides a standard bioinformation analysis process for proteomics analysis of the polyclonal antibodies, and can effectively, simply and reliably obtain specific antibodies with high specificity and good immunoreactivity from the polyclonal antibodies.

The invention relates to the molecular biology and tumor medicine fields, and relates to an application of a lung cancer marker SBP-1 in lung cancer diagnosis, and a method for detecting lung cancer by taking SBP-1 as the marker. According to the invention, a comparative proteomics method is employed for comparative analysis of protein expression profile of a lung cancer cell line/tissue and normal control cell/tissue, and a mass spectrum identifies the partial difference protein points. SBP-1 protein is a difference point, and enables high expression in cancer cells by comparing with that of the normal cells, and the difference is obvious. The invention employs RT-PCR and an immunohistochemical technology to respectively detect mRNA of SBP-1 and expression level of protein expression in normal tissue, the result displays that the expression of SBP-1 in the lung cancer tissue is obviously higher than that of its paired normal tissue, so that SBP-1 can be taken as a diagnosis marker of lung cancer. The invention also provides a lung cancer diagnostic kit and a detection method used for lung cancer.

The invention relates to an MAP2K1 marker for diagnosing the closing or opening of arterial ducts. The opened and closed arterial duct tissues are identified and analyzed through an ITRAQ proteomics method, and 132 different proteins are screened out; after signal path analysis is carried out, an MAP2K1 protein is selected; the MAP2K1 protein is identified with three methods including western blot, Qrt-PCR and immunofluorescence analysis, the expression of the protein in the arterial duct tissues of a human body is proved for the first time, and the protein has a significant difference in the closed and opened arterial duct tissues, so that the protein can be a key factor for regulating and controlling the closing or opening of the arterial ducts. The MAP2K1 protein can be used for clinical diagnosis of patent ductus arteriosus, and the accuracy of diagnosis is high.

The invention discloses a method for determining ancient silk fabrics by using peach gum gel slab electrophoresis. The ancient silk fabrics are degummed, dissolved, desalted, dialyzed and concentrated and then subjected to an electrophoresis experiment by using peach gum gel prepared in advance, wherein the peach gum gel has a space network structure, and the effect which is the same as that of sepharose gel after a series of treatment, and further has no pollution to the environment, thereby being higher in utilization values. Electrophoresis results of the ancient silk fabrics are subjected to enzymolysis by using a method of gel endoenzyme digestion and then mass spectrometry analysis by using HPLC-MS/MS, the results are compared with an amino acid sequence database, and the material types of the ancient silk fabrics are obtained according to amino acid sequences; according to the invention, the ancient silk fabrics are determined by using a proteomics method, so that on the one hand, the sensitivity is high and the operation is simple and convenient; on the other hand, the accuracy is high and the use amount of a sample is less.

The invention relates to a treponema pallidum IgG antibody biotin avidin enzyme-linked immune detection kit and a preparation method thereof, which relates to the syphilis detection. The kit comprises a concentrated washing liquid bottle, a negative and positive control bottle, a biotin mark antihuman IgG specific fragment gamma chain monoclonal antibody bottle, a horseradish peroxidase mark avidin bottle, a TMB coloured solution bottle A, a coloured solution bottle B, a reaction stopping solution bottle, a micropore plate coated with recombinant antigen. The treponema pallidum has infectious standard strain Nichol strain and treponema pallidum non-infectious standard strain Reiter strain, by using a proteomics method, the treponema pallidum proteomics can be separated through dimensional electrophoresis, protein with strong immunogenicity can be identified by different patient or infectious animal serum, and then an antigen marker can be searched. The antigen marker is used for syphilis confirmation test, so that diagnosis sensitivity and specificity can be increased, a window stage is shortened. The treponema pallidum antibody can be sensitively detected and enables quantitative measurement, and has the advantages of cheap price, simple operation and accurate result.

The invention relates to a method for screening a severe preeclampsia patient in an early pregnancy, which adopts plasma fibronectin FN and complement 4b of a pregnant woman in the early pregnancy as early pregnancy plasma markers for predicting sPE, and establishes a prediction model for predicting or assisting in predicting whether the pregnant woman progresses to the sPE patient, so that the sPE can be accurately predicted. The method has the beneficial effects that the plasma biological marker of the sPE pregnant woman at the early pregnancy stage is searched by adopting an MS-based proteomics method, and the differential expression plasma marker obtained by proteomics analysis is verified through a commercially available ELISA kit;through proteomics analysis and ELISA verification, based on the difference indexes in the pregnant woman baseline features and the difference indexes in the pregnant woman plasma biomarkers in the prospective queue, an early pregnancy prediction model of sPE is constructed, the prediction accuracy of sPE is improved, clinical early intervention is guided, the incidence rate of PE is reduced as much as possible, and adverse pregnancy events are reduced.

The invention relates to active protein or polypeptides derived from the human placenta and application of the active protein or polypeptides derived from the human placenta. The active protein or polypeptides derived from the human placenta or a combination of the active protein and the polypeptides, compositions of the active protein or the polypeptides or the combination of the active protein and the polypeptides, preparations of the active protein or the polypeptides or the combination of the active protein and the polypeptides, and application of the active protein or the polypeptides orthe combination of the active protein and the polypeptides, the compositions and the preparations are disclosed. By means of the human placenta which is positive for a surface antibody (HBsAb) of Hepatitis B Virus (HBV) and negative for a surface antigen (HBsAg) of the Hepatitis B Virus (HBV), small molecular substances in the human placenta are extracted, and are used to prepare injections, including a liquid injection and a powder injection. According to the invention, a proteomics method is used, the protein or the polypeptides in two kinds of placenta extracts are compared and analyzed, 110 kinds of human placenta active protein or polypeptides with specific immunity are obtained, and experiments prove that the extracts from the placenta which is positive for the surface antibody (HBsAb) of the Hepatitis B virus (HBV) have immunostimulation effects, and have significant therapeutic effects on Hepatitis B.